Abstract

Sonneratia apetala Buch-Ham., an exotic mangrove species with antidiabetic, antibacterial, and antioxidant capacities, mainly distributes in the southeast coastal areas in China. The present work investigated the protective effects of Sonneratia apetala leaves and branches extraction (SAL) on hyperuricemia (HUA) in mice. Potassium oxonate (PO) and hypoxanthine (HX) were used to establish the HUA model by challenge for consecutive 7 days. Results revealed that SAL inhibited the increases in kidney weight and index compared to the vehicle group. Meanwhile, SAL significantly decreased the levels of uric acid (UA), creatinine (CRE), and blood urea nitrogen (BUN) in serum. Additionally, SAL inhibited the activity of xanthine oxidase (XOD) in the liver. SAL ameliorated PO- and HX-induced histopathological changes. Moreover, it regulated oxidative stress markers including malondialdehyde (MDA), catalase (CAT), superoxide dismutase (SOD) activity, and glutathione (GSH) content. Also, SAL inhibited the increases in renal levels of interleukin-6 (IL-6), interleukin-18 (IL-18), interleukin-1β (IL-1β), tumor necrosis factor (TNF-α), monocyte chemotactic protein 1 (MCP-1), and transforming growth factor-β (TGF-β). SAL remarkably reduced suppressor of cytokine signaling 3 (SOCS3), Janus kinase 2 (JAK2), and subsequent phosphorylation of signal transducer and activator of transcription 3 (STAT3) expression. In addition, SAL inhibited the activation of nuclear factor kappa-B (NF-κB) in the kidney. Furthermore, SAL protected against HUA by regulating renal UA transporters of organic anion transporter (OAT1), urate reabsorption transporter 1 (URAT1), and glucose transporter 9 (GLUT9). These findings suggested that SAL ameliorated HUA by inhibiting the production of uric acid and enhancing renal urate excretion, which are related to oxidative stress and inflammation, and the possible molecular mechanisms include its ability to inhibit the JAK/STAT signaling pathway. Thus, SAL might be developed into a promising agent for HUA treatments.

Highlights

  • Hyperuricemia (HUA) is a metabolic disease caused by abnormal purine metabolism or insufficient uric acid (UA) excretion, characterized by elevated UA in the blood (Borghi, 2017; Dehlin et al, 2020)

  • The appearance of kidneys in the vehicle group confirmed that the HUA model was established successfully

  • Results in the present study indicated that Sonneratia apetala leaves and branches extraction (SAL) significantly decreased the xanthine oxidase (XOD) activity in the liver of the HUA mice, but the inhibitory effect of SAL is much weaker than FBX

Read more

Summary

Introduction

Hyperuricemia (HUA) is a metabolic disease caused by abnormal purine metabolism or insufficient uric acid (UA) excretion, characterized by elevated UA in the blood (Borghi, 2017; Dehlin et al, 2020). Hepatic overproduction and renal underexcretion of uric acid are two of the main causes of HUA (Shekelle et al, 2017). UA production is catalyzed by xanthine oxidase (XOD) in the liver, whereas excretion of UA occurs in the kidney. Accumulation of UA in the kidney can lead to UA crystals and cause inflammation and oxidative stress, thereby leading to kidney injury (Chang et al, 2014). Reducing UA production, promoting UA excretion, or (and) ameliorating the inflammation and oxidative stress may be the potential therapeutic methods of HUA

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call